Literature DB >> 20080878

Increased metabolic vulnerability in early-onset Alzheimer's disease is not related to amyloid burden.

Gil D Rabinovici1, Ansgar J Furst, Adi Alkalay, Caroline A Racine, James P O'Neil, Mustafa Janabi, Suzanne L Baker, Neha Agarwal, Stephen J Bonasera, Elizabeth C Mormino, Michael W Weiner, Maria L Gorno-Tempini, Howard J Rosen, Bruce L Miller, William J Jagust.   

Abstract

Patients with early age-of-onset Alzheimer's disease show more rapid progression, more generalized cognitive deficits and greater cortical atrophy and hypometabolism compared to late-onset patients at a similar disease stage. The biological mechanisms that underlie these differences are not well understood. The purpose of this study was to examine in vivo whether metabolic differences between early-onset and late-onset Alzheimer's disease are associated with differences in the distribution and burden of fibrillar amyloid-beta. Patients meeting criteria for probable Alzheimer's disease (National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's; Disease and Related Disorders Association criteria) were divided based on estimated age at first symptom (less than or greater than 65 years) into early-onset (n = 21, mean age-at-onset 55.2 +/- 5.9 years) and late-onset (n = 18, 72.0 +/- 4.7 years) groups matched for disease duration and severity. Patients underwent positron emission tomography with the amyloid-beta-ligand [(11)C]-labelled Pittsburgh compound-B and the glucose analogue [(18)F]-labelled fluorodeoxyglucose. A group of cognitively normal controls (n = 30, mean age 73.7 +/- 6.4) was studied for comparison. [(11)C]-labelled Pittsburgh compound-B images were analysed using Logan graphical analysis (cerebellar reference) and [(18)F]-labelled fluorodeoxyglucose images were normalized to mean activity in the pons. Group differences in tracer uptake were assessed on a voxel-wise basis using statistical parametric mapping, and by comparing mean values in regions of interest. To account for brain atrophy, analyses were repeated after applying partial volume correction to positron emission tomography data. Compared to normal controls, both early-onset and late-onset Alzheimer's disease patient groups showed increased [(11)C]-labelled Pittsburgh compound-B uptake throughout frontal, parietal and lateral temporal cortices and striatum on voxel-wise and region of interest comparisons (P < 0.05). However, there were no significant differences in regional or global [(11)C]-labelled Pittsburgh compound-B binding between early-onset and late-onset patients. In contrast, early-onset patients showed significantly lower glucose metabolism than late-onset patients in precuneus/posterior cingulate, lateral temporo-parietal and occipital corticies (voxel-wise and region of interest comparisons, P < 0.05). Similar results were found for [(11)C]-labelled Pittsburgh compound-B and [(18)F]-labelled fluorodeoxyglucose using atrophy-corrected data. Age-at-onset correlated positively with glucose metabolism in precuneus, lateral parietal and occipital regions of interest (controlling for age, education and Mini Mental State Exam, P < 0.05), while no correlations were found between age-at-onset and [(11)C]-labelled Pittsburgh compound-B binding. In summary, a comparable burden of fibrillar amyloid-beta was associated with greater posterior cortical hypometabolism in early-onset Alzheimer's disease. Our data are consistent with a model in which both early amyloid-beta accumulation and increased vulnerability to amyloid-beta pathology play critical roles in the pathogenesis of Alzheimer's disease in young patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20080878      PMCID: PMC2858015          DOI: 10.1093/brain/awp326

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  102 in total

1.  Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease.

Authors:  S Minoshima; B Giordani; S Berent; K A Frey; N L Foster; D E Kuhl
Journal:  Ann Neurol       Date:  1997-07       Impact factor: 10.422

2.  Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people. The Cardiovascular Health Study.

Authors:  W T Longstreth; T A Manolio; A Arnold; G L Burke; N Bryan; C A Jungreis; P L Enright; D O'Leary; L Fried
Journal:  Stroke       Date:  1996-08       Impact factor: 7.914

3.  Cerebral glucose metabolism in patients with AD and different APOE genotypes.

Authors:  A Drzezga; M Riemenschneider; B Strassner; T Grimmer; M Peller; A Knoll; S Wagenpfeil; S Minoshima; M Schwaiger; A Kurz
Journal:  Neurology       Date:  2005-01-11       Impact factor: 9.910

4.  Age at onset of Alzheimer's disease: relation to pattern of cognitive dysfunction and rate of decline.

Authors:  D Jacobs; M Sano; K Marder; K Bell; F Bylsma; G Lafleche; M Albert; J Brandt; Y Stern
Journal:  Neurology       Date:  1994-07       Impact factor: 9.910

5.  Comparison of the severity of neuropathologic changes in familial and sporadic Alzheimer's disease.

Authors:  D Nochlin; G van Belle; T D Bird; S M Sumi
Journal:  Alzheimer Dis Assoc Disord       Date:  1993       Impact factor: 2.703

6.  Clinical and pathological correlates of apolipoprotein E epsilon 4 in Alzheimer's disease.

Authors:  T Gomez-Isla; H L West; G W Rebeck; S D Harr; J H Growdon; J J Locascio; T T Perls; L A Lipsitz; B T Hyman
Journal:  Ann Neurol       Date:  1996-01       Impact factor: 10.422

7.  Clinical and neuropsychological differences between patients with earlier and later onset of Alzheimer's disease: A CERAD analysis, Part XII.

Authors:  E Koss; S Edland; G Fillenbaum; R Mohs; C Clark; D Galasko; J C Morris
Journal:  Neurology       Date:  1996-01       Impact factor: 9.910

8.  Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E.

Authors:  E M Reiman; R J Caselli; L S Yun; K Chen; D Bandy; S Minoshima; S N Thibodeau; D Osborne
Journal:  N Engl J Med       Date:  1996-03-21       Impact factor: 91.245

9.  Neuropsychological heterogeneity in mild Alzheimer's disease.

Authors:  G Binetti; E Magni; A Padovani; S F Cappa; A Bianchetti; M Trabucchi
Journal:  Dementia       Date:  1993 Nov-Dec

10.  Preserved pontine glucose metabolism in Alzheimer disease: a reference region for functional brain image (PET) analysis.

Authors:  S Minoshima; K A Frey; N L Foster; D E Kuhl
Journal:  J Comput Assist Tomogr       Date:  1995 Jul-Aug       Impact factor: 1.826

View more
  119 in total

1.  Coronary risk correlates with cerebral amyloid deposition.

Authors:  Bruce R Reed; Natalie L Marchant; William J Jagust; Charles C DeCarli; Wendy Mack; Helena C Chui
Journal:  Neurobiol Aging       Date:  2011-11-10       Impact factor: 4.673

Review 2.  Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia.

Authors:  William E Klunk
Journal:  Neurobiol Aging       Date:  2011-12       Impact factor: 4.673

3.  Cerebrovascular disease, β-amyloid, and cognition in aging.

Authors:  Natalie L Marchant; Bruce R Reed; Charles S DeCarli; Cindee M Madison; Michael W Weiner; Helena C Chui; William J Jagust
Journal:  Neurobiol Aging       Date:  2011-11-01       Impact factor: 4.673

4.  Functional connectivity changes differ in early and late-onset Alzheimer's disease.

Authors:  Natalina Gour; Olivier Felician; Mira Didic; Lejla Koric; Claude Gueriot; Valérie Chanoine; Sylviane Confort-Gouny; Maxime Guye; Mathieu Ceccaldi; Jean Philippe Ranjeva
Journal:  Hum Brain Mapp       Date:  2013-10-05       Impact factor: 5.038

Review 5.  The corticobasal syndrome-Alzheimer's disease conundrum.

Authors:  Anhar Hassan; Jennifer L Whitwell; Keith A Josephs
Journal:  Expert Rev Neurother       Date:  2011-11       Impact factor: 4.618

6.  Instrumental activities of daily living impairment is associated with increased amyloid burden.

Authors:  Gad A Marshall; Lauren E Olson; Meghan T Frey; Jacqueline Maye; J Alex Becker; Dorene M Rentz; Reisa A Sperling; Keith A Johnson
Journal:  Dement Geriatr Cogn Disord       Date:  2011-07-20       Impact factor: 2.959

7.  Not quite PIB-positive, not quite PIB-negative: slight PIB elevations in elderly normal control subjects are biologically relevant.

Authors:  Elizabeth C Mormino; Michael G Brandel; Cindee M Madison; Gil D Rabinovici; Shawn Marks; Suzanne L Baker; William J Jagust
Journal:  Neuroimage       Date:  2011-08-22       Impact factor: 6.556

8.  Mapping the Progression of Atrophy in Early- and Late-Onset Alzheimer's Disease.

Authors:  Raffaella Migliaccio; Federica Agosta; Katherine L Possin; Elisa Canu; Massimo Filippi; Gil D Rabinovici; Howard J Rosen; Bruce L Miller; Maria Luisa Gorno-Tempini
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

Review 9.  Late-onset Alzheimer Disease.

Authors:  Gil D Rabinovici
Journal:  Continuum (Minneap Minn)       Date:  2019-02

Review 10.  Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta.

Authors:  Ann D Cohen; Gil D Rabinovici; Chester A Mathis; William J Jagust; William E Klunk; Milos D Ikonomovic
Journal:  Adv Pharmacol       Date:  2012
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.